â–ª Diagnosis and localisation of adrenal-and extra-adrenal PCC/PGL in patients with elevated catecholamine levels. |
â–ª Staging of patients prior to surgical resection to exclude metastatic or additional primary sites of disease. |
â–ª Selection of patients for radionuclide therapy with 177Lu/90Y radiolabelled DOTATATE or 131I-MIBG therapy. |
â–ª Response assessment following chemotherapy or targeted therapies. |
â–ª Surveillance of patients with inherited mutations such as SDHxor VHL |